Our Approach

Equipped with a unique understanding of the immune suppressive dynamics that allow cancer cells to grow and spread in the body, we are moving beyond T-cell targeted therapies to develop novel biotherapeutics that navigate and disarm immune suppression and tumor infiltration.

Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute myeloid leukemia (AML) and other cancers.

 
02-Our-Approach2.jpg
 

PipelinE

 
 
IO-202
Acute myeloid leukemia and other hematologic and solid tumors
 IND-Enabling Studies
Undisclosed Program
Solid tumors
Pre-Clinical
Multiple Undisclosed Programs
Acute myeloid leukemia and other hematologic and solid tumors
Pre-Clinical
 
 
 

Publications & Abstracts

Assembled below are selected peer-reviewed research papers and abstracts authored by Immune-Onc scientists and our collaborators.

 
03-Publications-&-Abstracts2.jpg
 

Deng M. et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018; DOI: 10.1038/s41586-018-0615-z.

John S. et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol. Ther. 2018; 26: 2487-2495.